Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record.

Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial

Crinò, Lucio, Mosconi, Anna Maria, Scagliotti, Giorgio, Selvaggi, Giovanni, Novello, Silvia, Rinaldi, Massimo, Della Giulia, Marina, Gridelli, Cesare, Rossi, Antonio, Calandri, Cesare, De Marinis, Filippo, Noseda, Mariantonietta, Tonato, Maurizio · 1999 · Journal of Clinical Oncology

Abstract

PURPOSE: To investigate the activity and toxicity of gemcitabine as a single agent in patients with advanced non–small-cell lung cancer (NSCLC) after recurrence or failure of previous treatment with a platinum-containing regimen. PATIENTS AND METHODS: From November 1995 to October 1997, 83 patients with stage IIIB or IV NSCLC received gemcitabine 1,000 mg/m 2 once a week for 3 weeks every 28 days. Responses were assessed every two treatment courses. The median age of the patients was 63 years; Eastern Cooperative Oncology Group performance status was 0 to 1 in 62 patients and 2 in 21 patients. The predominant histology was squamous (39 patients); 49 patients had stage IV disease and 34 patients had stage III disease (33 stage IIIB and one stage IIIA). RESULTS: Sixteen patients (19%) achieved a partial response to treatment; the median duration of response was 29 weeks (range, 6 to 50 weeks). Treatment was well tolerated: grade 2 to 3 (World Health Organization standardized response criteria) leukopenia and thrombocytopenia occurred in 23% and 20% of patients, respectively. Mild asthenia was observed in 16% of patients, and peripheral edema in 5% of patients. Nausea and vomiting were present in 16% of patients. CONCLUSION: In this experience, gemcitabine showed significant activity without relevant toxicity, mainly in patients who were previously responsive to chemotherapy. This suggests a possible role for gemcitabine as a second-line treatment in patients who had a previous response or achieved stable disease with a platinum-containing regimen.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.7.2081

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 162

Metadata

Authors
Crinò, L., Mosconi, A. M., Scagliotti, G., Selvaggi, G., Novello, S., Rinaldi, M., Della Giulia, M., Gridelli, C., Rossi, A., Calandri, C., De Marinis, F., Noseda, M., & Tonato, M.
Venue
Journal of Clinical Oncology
Published
1999-07
Volume
17
Issue
7
Pages
2081-2081
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1911047310
Cited by
162
References
0
FWCI
17.20
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial. https://app.cochat.ai/papers/10.1200/jco.1999.17.7.2081
The paper
Crinò, L., Mosconi, A. M., Scagliotti, G., Selvaggi, G., Novello, S., Rinaldi, M., Della Giulia, M., Gridelli, C., Rossi, A., Calandri, C., De Marinis, F., Noseda, M., & Tonato, M. (1999). Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.7.2081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.